As of May 27, 2025, CHINA PHARMAHUB ORD (CPHB) reports a ROA (Return on Assets) of -231.21%.
ROA (Return on Assets) evaluates how effectively a company turns its assets into profits, showcasing resource utilization.
Comparing CHINA PHARMAHUB ORD's ROA (Return on Assets) to Peers
To better understand CHINA PHARMAHUB ORD's position, it's useful to compare its ROA (Return on Assets) against industry peers. Below are selected comparisons:
| Company | ROA (Return on Assets) |
|---|---|
| CHINA PHARMAHUB ORD (CPHB) | -231.21% |
| Gossamer Bio Inc (GOSS) | -17.93% |
| Xeno Transplants Corp (XENO) | -19.99% |
| Caladrius Biosciences Inc (CLBS) | -28.31% |
| Karuna Therapeutics Inc (KRTX) | -32.46% |
| Stromacel Inc (PROT) | -41.42% |
Compared to its competitors, CHINA PHARMAHUB ORD's ROA (Return on Assets) is about average compared to peers, indicating typical asset efficiency for the industry.